Disc Medicine Soars 60% on Positive Phase 3 Trial for Rare Sunlight Disorder

Disc Medicine (NASDAQ: IRON) shares surged 60% premarket after its Phase 3 APOLLO trial for bitopertin, an investigational treatment for erythropoietic protoporphyria (EPP), met all primary and secondary endpoints .

Key highlights:

• Reduced Toxic Buildup: 41.4% reduction in whole-blood metal-free protoporphyrin IX.
• Increased Light Exposure: Patients gained 12.2 hours of pain-free light exposure monthly.
• Improved Safety: Generally well-tolerated with mild/moderate dizziness as the most common side effect.

The company plans to resubmit a New Drug Application (NDA) to the FDA by end of 2026, with a regulatory decision anticipated by mid-2027 .